The CD70-targeting CTX131 heads for the scrapheap.
ApexOnco Front Page
Recent articles
Bezuclastinib plus Sutent could become standard of care in second-line GIST.
Merck and Daiichi’s first ADC attempt is knocked back, while Geron gets its inaugural approval.
Farletuzumab ecteribulin follows its parent MAb with a setback, spelling possible bad news for Sutro.
The EU recommendation for odronextamab comes after a US rejection in March.
But ficerafusp is limited to HPV-negative disease, and petosemtamab’s safety looks better.
Predictably Tacti-003 fails, but funding is secured – from investors, not a partner.
A complete response letter for Merck & Co and Daiichi’s patritumab deruxtecan might not be fatal, but it’s certainly embarrassing.